ICKER CODE: ATOS
Company Name: ATOSSA THERAPEUTICS, INC
Industry: US Stocks Health Technology Medical Specialties
Position Proposed: BUY
FOMO BUY ENTRY: NOW READY (4.00-5.20)
NEXT BUY ENTRY: (2,65 - 3.35)
1st Partial Take Profit: 140.00 (Mid 2022)
2nd Partial Take Profit: 200.00 (Mid 2024)
3RD Partial Take Profit: 320.00 (2027)
1st PARTIAL SHORT TERM TP: 30:200
2nd PARTIAL SHORT TERM TP: 140.00
Stop Loss: 3.00
Technical Analysis
1. FALLING WEDGE PATTERN (COMPLETED )
2. HEAD & SHOULDERS PATTERN (PARTIALLY COMPLETE)
2. Area of Confluence on EMA & structure level
4. Fibonacci Retracement at 0.618 OR 0.786
5. Safest Take Profit will land 80 % equivalent to the length of head and neckline
level 2 of Fibonacci Expansion Blue Zone
Company Name: ATOSSA THERAPEUTICS, INC
Industry: US Stocks Health Technology Medical Specialties
Position Proposed: BUY
FOMO BUY ENTRY: NOW READY (4.00-5.20)
NEXT BUY ENTRY: (2,65 - 3.35)
1st Partial Take Profit: 140.00 (Mid 2022)
2nd Partial Take Profit: 200.00 (Mid 2024)
3RD Partial Take Profit: 320.00 (2027)
1st PARTIAL SHORT TERM TP: 30:200
2nd PARTIAL SHORT TERM TP: 140.00
Stop Loss: 3.00
Technical Analysis
1. FALLING WEDGE PATTERN (COMPLETED )
2. HEAD & SHOULDERS PATTERN (PARTIALLY COMPLETE)
2. Area of Confluence on EMA & structure level
4. Fibonacci Retracement at 0.618 OR 0.786
5. Safest Take Profit will land 80 % equivalent to the length of head and neckline
level 2 of Fibonacci Expansion Blue Zone
Note
HI ALL, ATOS HIT SHORT-TERM 1st TPPlease Exit positions as our RSI is currently overbought.
We will look for re-entry
just note that it could potentially reach 8.30 before plunge down.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.